Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

BeOne Medicines (BEIGF) Operating Expenses (2016 - 2025)

BeOne Medicines (BEIGF) has disclosed Operating Expenses for 11 consecutive years, with $1.2 billion as the latest value for Q4 2025.

  • Quarterly Operating Expenses rose 11.85% to $1.2 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.2 billion through Dec 2025, up 11.71% year-over-year, with the annual reading at $4.2 billion for FY2025, 11.71% up from the prior year.
  • Operating Expenses for Q4 2025 was $1.2 billion at BeOne Medicines, up from $1.1 billion in the prior quarter.
  • The five-year high for Operating Expenses was $1.2 billion in Q4 2025, with the low at -$1.2 billion in Q4 2021.
  • Average Operating Expenses over 5 years is $744.7 million, with a median of $822.5 million recorded in 2022.
  • The sharpest move saw Operating Expenses tumbled 297.07% in 2021, then soared 148.77% in 2022.
  • Over 5 years, Operating Expenses stood at -$1.2 billion in 2021, then skyrocketed by 148.77% to $562.2 million in 2022, then surged by 62.27% to $912.4 million in 2023, then grew by 14.72% to $1.0 billion in 2024, then increased by 11.85% to $1.2 billion in 2025.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $1.2 billion, $1.1 billion, and $1.1 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.